Liquid Micro Sprayer Aerosolizer （ for large animals）

Product instroduction
The 30014 Liquid Micro Sprayer Aerosolizerx ( Pulmonary Liquid Nebulizer), also referred to as an intratracheal aerosol delivery device, is purpose-built for large animals such as rabbits and non-human primates, enabling precise and quantified intratracheal aerosolized drug delivery. A metered volume of liquid is aerosolized through a micron-scale atomizing nozzle integrated into a stainless-steel capillary cannula. The cannula is advanced into the airway to the tracheal bifurcation, delivering a quantified aerosol directly into the lungs. Compared with conventional oral or injection administration, the drug acts directly on the pulmonary tissue, making the device ideal for pulmonary physiology, pathology and pharmacology research.

Key Features

1. Advanced Liquid Atomization

2. Precise Dose Control

3. Multiple Drug Formulations

4. Design & Materials

5. Easy Operation

Technical Specifications

• Suitable for solutions, small-cell suspensions (< 15 μm), homogeneous suspensions and low-viscosity emulsions; dosing range 25–250 μL or 25–500 μL.
• Drug droplet diameter: 10–30 μm
• Reaches bronchioles and terminal bronchioles
• Single-dose aerosolization accuracy: 2 μL
• Nozzle outer diameter: ≤ 0.8 mm
• Atomizing needle length: ≥ 30 cm; custom lengths supported

1. High-Pressure Atomizing Dispenser — certified precision, “each particle delivered distinctly”

• Micro-volume accurate dosing, minimum 25 μL
• 90% of droplets < 30 μm, evenly distributed in lung tissue

2. Two syringe volumes to choose from — customized to meet your needs

Provides 250 μL or 500 μL syringe volumes, meeting the diverse needs of experiments.

3. 25 / 50 μL Quantitative Stoppers — free combination, precise dosing

• Standard: 4×25 μL + 4×50 μL, freely combinable
• Custom: 40 μL or other sizes available per dosing requirements

The pulmonary nebulizer delivers a quantified aerosol intratracheally. It is primarily used for establishing pulmonary-disease animal models and for pulmonary drug delivery.

1. Pulmonary Disease Animal Models

The pulmonary nebulizer can be used to establish a variety of respiratory-disease models for studying disease mechanisms and evaluating therapeutic efficacy, including but not limited to the following:

• Acute Lung Injury Model — The device delivers a quantified dose of LPS (lipopolysaccharide) directly into the lungs to simulate the pathological state of acute lung injury.
• Pulmonary Fibrosis Model — A quantified dose of bleomycin is delivered into the lungs of healthy animals to induce pulmonary fibrosis.
• Asthma Model — Antigens or allergens (e.g., ovalbumin) are aerosolized and inhaled into the lungs, inducing symptoms similar to human asthma — airway inflammation, bronchoconstriction and airway hyperresponsiveness.

2. Pulmonary Drug Delivery
Medication is delivered directly to the tracheal bifurcation for efficacy testing, including but not limited to drugs that induce tumor-cell apoptosis, drugs that inhibit pulmonary fibrosis, and anti-acute-lung-infection agents.

3. Nasal drug delivery studies 
Try to use for nasal drug delivery studies in laboratory animals. By delivering drugs in the form of micro-sprays to the nasal mucosa, drugs can be absorbed through the nose into the systemic circulation or directly enter the central nervous system through the naso-brain pathway . They are used for drug development for central nervous system diseases (such as neurodegenerative diseases), nasal local drug delivery studies, and evaluation of systemic drug delivery routes. They are also suitable for studying the delivery mechanism of peptides, nucleic acids, and macromolecular drugs, pharmacokinetic analysis, and formulation development evaluation. Furthermore, they can improve drug delivery uniformity, reduce operational variability, shorten drug delivery time, and improve experimental efficiency and repeatability.